Feiba VH Immuno


Indications and Reactions:

Role Indications Reactions
Primary
Drug Use For Unknown Indication 22.5%
Factor Viii Deficiency 11.9%
Factor Viii Inhibition 11.1%
Haemostasis 9.0%
Haemorrhage 6.6%
Acquired Haemophilia 5.3%
Haemophilia 4.1%
Prophylaxis 4.1%
Haematuria 3.3%
Post Procedural Haemorrhage 3.3%
Haemophilia B With Anti Factor Ix 2.9%
Asthma 2.5%
Joint Surgery 2.5%
Haemarthrosis 2.0%
Off Label Use 2.0%
Factor Ix Inhibition 1.6%
Hypertension 1.6%
Epilepsy 1.2%
Haematoma 1.2%
Haemorrhage Control 1.2%
Drug Ineffective 12.3%
Vomiting 11.1%
Myocardial Infarction 9.9%
Thrombosis 7.4%
Cerebral Haemorrhage 6.2%
Factor Viii Inhibition 6.2%
Disseminated Intravascular Coagulation 4.9%
Pulmonary Oedema 4.9%
Haemorrhage 3.7%
Pneumonia 3.7%
Pulmonary Embolism 3.7%
Pyrexia 3.7%
Respiratory Failure 3.7%
Throat Tightness 3.7%
Blood Pressure Increased 2.5%
Chills 2.5%
Death 2.5%
Head Injury 2.5%
Mass 2.5%
Multi-organ Failure 2.5%
Secondary
Drug Use For Unknown Indication 19.6%
Joint Surgery 19.6%
Haemophilia 7.7%
Factor Viii Deficiency 7.0%
Epilepsy 5.8%
Haemostasis 5.3%
Haemorrhage 4.9%
Acquired Haemophilia 3.9%
Haemophilia B With Anti Factor Ix 3.7%
Factor Viii Inhibition 3.3%
Haematoma 3.3%
Haemophilia A With Anti Factor Viii 2.5%
Hypothyroidism 1.9%
Muscle Haemorrhage 1.9%
Bronchitis 1.8%
Haematemesis 1.8%
Immunosuppression 1.6%
Infection Prophylaxis 1.6%
Prophylaxis 1.6%
Haemarthrosis 1.4%
Factor Viii Inhibition 36.6%
Haematoma 11.5%
Hepatitis C Virus 5.5%
Vomiting 5.5%
Drug Ineffective 5.1%
Haemorrhage Intracranial 4.7%
Myocardial Infarction 4.7%
Chills 4.3%
Pneumonia 3.8%
Disseminated Intravascular Coagulation 2.6%
Mass 2.6%
Respiratory Failure 2.1%
Cerebral Haemorrhage 1.7%
Oedema 1.7%
Pulmonary Oedema 1.7%
Chest Pain 1.3%
Hypersensitivity 1.3%
Platelet Count Decreased 1.3%
Thrombosis 1.3%
Hepatic Failure 0.9%
Concomitant
Hiv Infection 100.0%
Depression 100.0%

Drug Data